This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BINOSTO® (alendronate Sodium) Named To BioCentury's Products To Watch In 2013









SAN ANTONIO, Texas, Jan. 22, 2013 /PRNewswire/ -- BINOSTO® (alendronate sodium) Effervescent Tablet for oral solution 70 mg, was named a "Product to Watch" in the January 7, 2013, edition of BioCentury, the Bernstein Report on BioBusiness newsletter.  BioCentury is an internationally recognized leader in providing pharmaceutical analysis and data, along with value-added information for biotechnology and pharmaceutical companies. BINOSTO, a product of Mission Pharmacal and the first and only buffered solution of alendronate for the treatment of osteoporosis, was approved in 2012 by the U.S. Food and Drug Administration to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

BINOSTO delivers the gold standard of alendronate sodium, the most broadly prescribed osteoporosis treatment for fracture prevention at the hip and spine, in a pleasant-tasting, once-weekly, buffered solution.  BINOSTO also requires 50 percent less water than other alendronate products (4 ounces versus 8 ounces) and, because there is no tablet, patients can rest assured that they will not experience tablet esophagitis.  The product represents a true innovation in the delivery of osteoporosis and bone fracture prevention medication, especially for those patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.

"Osteoporosis is widespread, with serious consequences for patients, including mortality, which is often seen after suffering a hip fracture.  In fact, a 50-year-old woman's lifetime risk of dying from a hip fracture is equal to her risk of dying from breast cancer.  And, unfortunately, many people incorrectly consider osteoporosis to be a normal part of aging.  That's because it is largely asymptomatic,"[i]  said Sol Epstein, MD, professor of medicine and geriatrics at Mount Sinai School of Medicine in New York.  "But osteoporosis is treatable.  With the many new treatment options available, there is no reason for women to suffer the loss of independence and the pain and even mortality associated with osteoporotic fractures."

For anyone with osteoporosis, the best protection against suffering from a fracture is taking medications as prescribed by an authorized healthcare provider.  Taken just once a week, strawberry flavored BINOSTO offers an easy-to-take option for patients seeking to decrease their risks of suffering a disabling fracture.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs